Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab

Purpose: Immune checkpoint inhibitors (ICI) are a significant advance to the treatment of advanced non–small cell lung cancer (NSCLC); however, their initiation is associated with heterogeneity in outcomes. This study aimed to develop and validate a prognostic tool of survival in patients with advanced NSCLC treated with ICIs. Experimental Design: A pretreatment prognostic model was developed and validated using clinicopathologic data....